Labcorp Holdings Inc. (LH) Stock Price & Analysis
Labcorp Holdings Inc. (LH) rose 3.52% to USD 271.24 as of June 9, 2026 at 23:35 UTC, according to Nexqual real-time market data.
LH last closed at USD 262.01; the session ranged USD 262.43–271.33 on volume of 401,106 shares. Market capitalization is $22.24B, with a 52-week range of USD 241.81–293.72 (NYQ). Source: Nexqual, June 9, 2026 at 23:35 UTC.
Key Statistics (as of June 9, 2026 at 23:35 UTC)
| Price | USD 271.24 |
|---|---|
| Change | ▲ 3.52% (up) |
| Previous Close | USD 262.01 |
| Open | USD 263.68 |
| Day Range | USD 262.43 – 271.33 |
| 52-Week Range | USD 241.81 – 293.72 |
| Volume | 401,106 shares |
| Market Cap | $22.24B |
| Exchange | NYQ |
Technical Analysis (LH)
Nexqual's technical model rates LH "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.67 (neutral) |
| vs SMA50 | Above (USD 262.16) |
| MACD | 1.17 (positive) |
Analyst Ratings (LH)
Wall Street analysts rate LH "Buy" based on 17 analysts, with a mean price target of USD 310.12 (range USD 270–340), per Nexqual as of June 9, 2026 at 23:35 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 310.12 |
| High Target | USD 340 |
| Low Target | USD 270 |
| Buy / Hold / Sell | 15 / 4 / 0 |
Earnings (LH)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 4.78 |
| Revenue Estimate | $3.71B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.25 vs est 4.12 ▲ beat |
| 2025-12-31 | USD 4.07 vs est 3.94 ▲ beat |
| 2025-09-30 | USD 4.18 vs est 4.14 ▲ beat |
| 2025-06-30 | USD 4.35 vs est 4.16 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financials & Fundamentals (LH)
| Total Revenue | $14.14B |
|---|---|
| Revenue Growth (YoY) | +5.80% |
| Gross Margin | +28.83% |
| Operating Margin | +10.95% |
| Profit Margin | +6.66% |
| ROE | +11.05% |
| Debt / Equity | 83.41 |
| Current Ratio | 1.73 |
| Total Cash | $981.10M |
| Total Debt | $7.29B |
| Free Cash Flow | $1.14B |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financial Health Score (LH)
Nexqual rates Labcorp Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:35 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 29%, operating 11% |
| Balance Sheet | Mixed — $981M cash vs $7.29B debt |
| Cash Flow | Solid — FCF $1.14B, 8% margin |
| Efficiency | Mixed — ROE 11%, ROA 5.3% |
Ownership (LH)
| Insider Ownership | +0.35% |
|---|---|
| Institutional Ownership | +101.22% |
| Shares Outstanding | 82.00M |
| Float | 81.60M |
| Short % of Float | +4.12% |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Leadership (LH)
Labcorp Holdings Inc. is led by Adam H. Schechter (age 60), President, CEO & Chairman, per Nexqual as of June 9, 2026 at 23:35 UTC.
| President, CEO & Chairman | Adam H. Schechter (age 60) |
|---|---|
| CFO & Executive VP | Julia A. Wang (age 53) |
| EVP, President of Early Development Research Laboratories and Chief Medical & Scientific Officer | Brian J. Caveney J.D., M.D., M.P.H. (age 51) |
| Executive VP and President of Central Laboratory Services & International Labcorp | Megan D. Bailey M.P.H. (age 45) |
| Vice President of Investor Relations | Christin O'Donnell |
Major Backers & Investors (LH)
Notable institutional backers of Labcorp Holdings Inc. include Victory Capital Management Inc., Boston Partners, Allspring Global Investments Holdings, LLC, according to Nexqual as of June 9, 2026 at 23:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Victory Capital Management Inc. | 5.64% |
| Boston Partners | 2.89% |
| Allspring Global Investments Holdings, LLC | 2.72% |
| Select Equity Group LP | 2.65% |
| JPMorgan | 1.87% |
| ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund | 1.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.91% |
| BlackRock | 9.17% |
| State Street | 5.92% |
| Geode Capital | 2.67% |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
From Labcorp Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Labcorp Holdings Inc. provides laboratory services.
- It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services.
- The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
- It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DGX | Quest Diagnostics Incorporated | USD 204.53 | ▲ 2.12% |
| WAT | Waters Corporation | USD 371.15 | ▲ 1.58% |
| UHS | Universal Health Services, Inc. | USD 146.59 | ▲ 0.98% |
| IQV | IQVIA Holdings, Inc. | USD 186.25 | ▲ 1.53% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:35 UTC. This page is informational and not investment advice.